Evidence method
Level · gp.fundamentals.debt_to_revenue
107.90% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Mar 31, 2021
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-21-000017General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
9.67% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-132.72% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
78.50% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
41.64% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
87.03% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-104.89% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
104.69% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
31.36% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 14.28%
- Current
- 9.67%
- Delta
- -4.60%
- Previous
- -124.78%
- Current
- -132.72%
- Delta
- -7.94%
- Previous
- 124.28%
- Current
- 78.50%
- Delta
- -45.78%
- Previous
- 15.26%
- Current
- 41.64%
- Delta
- 26.38%
- Previous
- 84.16%
- Current
- 87.03%
- Delta
- 2.87%
- Previous
- -168.09%
- Current
- -104.89%
- Delta
- 63.20%
- Previous
- 132.86%
- Current
- 104.69%
- Delta
- -28.17%
- Previous
- 28.38%
- Current
- 31.36%
- Delta
- 2.98%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.